CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
about
Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary studyInvolvement of beta-chemokines in the development of inflammatory demyelinationHypersensitivity Responses in the Central Nervous SystemPlasma biomarkers discriminate clinical forms of multiple sclerosisExpression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica.Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis opticaMarkedly increased IP-10 production by blood-brain barrier in neuromyelitis opticaCC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells.Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.An Experimental Animal Model of Photodynamic Optic Nerve Head Injury (PONHI).Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patientsChemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.G protein-coupled receptors as therapeutic targets for multiple sclerosis.Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotypeInterferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications.Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations.Theiler's virus infection provokes the overexpression of genes coding for the chemokine Ip10 (CXCL10) in SJL/J murine astrocytes, which can be inhibited by modulators of estrogen receptors.Chemokines CXCL10 and CXCL11 in the cerebrospinal fluid of patients with tick-borne encephalitis.The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity.Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis.Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders.Chemokines and chemokine receptors in inflammation of the CNS.TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17.Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis.Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis
P2860
Q21558554-B30E58F6-C768-48BC-8547-7443A87E7EB3Q24801279-79B8831A-3290-4766-9A29-C0439DC41D9EQ26779177-5BE42814-62F2-4A65-8D49-B7EBCD804E97Q28262774-9165ADB5-1B22-44DB-9D98-0E966741A316Q33743686-CB64F52C-D688-4BA6-AD26-39F762CD103DQ33808279-360BC7D8-8370-4764-A84F-E8AF7636814DQ33904273-DBE9927F-9BB9-4DF0-AA22-4CAE3B18E537Q34235490-8E9ABF44-47D8-4CC8-86B2-455F9170FC0BQ34700673-03C00F63-85FF-464F-BF29-F5633D6110AFQ35067939-F0D1B590-3063-4DC5-9808-537C09B135BEQ35219651-AEDFA631-4452-40D0-997B-7519F569348EQ35844943-34651D28-844C-4390-81CC-20F1E007F4FEQ35863912-09F80789-1BA6-4FC4-B9B7-DC71EF4D8711Q36012050-9B21FDBC-F96C-481A-9708-D325AEE6AFE2Q36091339-20BBCA4E-D471-48F2-A55F-54CE34850713Q36734084-870F54C3-69D2-4D35-A977-8C6936315ED3Q37112554-A471C876-7D95-48E3-AEF1-B2962137A549Q37301528-AE05B177-B0BE-42FE-B8CF-CFEBA657FFD9Q37348839-E87CF3C1-88EB-41D6-BBA6-D7733ED2F414Q38171871-E69FA5FE-5ECE-41EC-B040-596BB8F1E9BCQ40099671-D4D7CF44-D130-4210-B40F-5E2B51166436Q42204508-1B464E05-B029-4C6A-8EFD-9B856C3ADCC2Q43034994-1CE72D91-B331-44AB-93A3-105D016D22EBQ47114458-D3D4305B-44BF-41FC-B8FD-3A6EA960CA09Q48275557-C455072D-F795-4FE1-B144-922DDA7FF0FDQ48726201-21FCE01A-9364-4D83-9282-C08B4E897280Q48771858-5A9651A7-74C5-4479-8183-82BD959B0B5BQ48829652-B78FAD21-A807-45AD-872A-A3B13FB6ED77Q52644010-7CA31E90-7F6A-414C-81CD-2D3D5069509EQ53627732-BAEA354E-E938-4387-8935-B6750CF161C4Q56771952-6C8F01C1-3B8C-4478-900E-37D44B06BB5DQ58857634-B7D24B2B-421A-43A4-AE10-EF604D68DB33
P2860
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
@en
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
@nl
type
label
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
@en
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
@nl
prefLabel
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
@en
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
@nl
P2093
P1476
CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
@en
P2093
Kazuo Fujihara
Koichi Narikawa
Shigeru Sato
Tatsuro Misu
Yasuto Itoyama
P304
P356
10.1016/J.JNEUROIM.2003.12.010
P577
2004-04-01T00:00:00Z